Antigen-specific active immunotherapy for ovarian cancer - Wikidata - wikimedia - TriplyDB

Antigen-specific active immunotherapy for ovarian cancer

Antigen-specific active immunotherapy for ovarian cancer

http://www.wikidata.org/entity/Q24240962

about

Antigen-specific active immunotherapy for ovarian cancer Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancer Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Deciphering the molecular nature of ovarian cancer biomarker CA125 Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.Immunotherapy in ovarian cancer.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

P2860

Q24193567-68FDA862-7F70-4ED7-A419-76479318A007 Q24235072-C66260E7-B21B-40FA-827B-26EE9F454428 Q26996829-4A958721-E695-4EE2-BBBD-D3B105ADF3DF Q27015008-28A6AA6E-11AC-43AE-8897-C7EB13259865 Q34290698-A0DCF060-C13C-4F4F-8EAA-7B918F9F2BEC Q36631249-F0E45780-C80B-4553-94DA-7301D700832B Q36958112-661021EA-6E41-42FE-9AB9-BD9667477619

P2860

Antigen-specific active immunotherapy for ovarian cancer

http://www.wikidata.org/entity/Q24240962

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Antigen-specific active immunotherapy for ovarian cancer

@ast

Antigen-specific active immunotherapy for ovarian cancer

@en

Antigen-specific active immunotherapy for ovarian cancer

@en-gb

Antigen-specific active immunotherapy for ovarian cancer

@nl

type

label

Antigen-specific active immunotherapy for ovarian cancer

@ast

Antigen-specific active immunotherapy for ovarian cancer

@en

Antigen-specific active immunotherapy for ovarian cancer

@en-gb

Antigen-specific active immunotherapy for ovarian cancer

@nl

prefLabel

Antigen-specific active immunotherapy for ovarian cancer

@ast

Antigen-specific active immunotherapy for ovarian cancer

@en

Antigen-specific active immunotherapy for ovarian cancer

@en-gb

Antigen-specific active immunotherapy for ovarian cancer

@nl

P1433

Q24240962-DAE805C6-E91D-45C1-AB10-A681C41F33A1

P1476

Q24240962-4036BCCD-52AA-4C6E-B5E8-F41621B03395

P2093

Q24240962-64152031-F143-4A4D-8A01-1EEFEA9BF40E

Q24240962-65643041-EE75-4389-B52F-0D8B660B4417

Q24240962-8C9128D7-5DDA-498C-B6A6-7D24458785EE

Q24240962-A6B3F62C-07F3-42C1-BF6B-ABBE15306F2F

Q24240962-AEF36E93-CFF4-480C-A0EC-947B19B6CEB4

Q24240962-CB55F7EF-3A36-47A1-82DE-B6A403C22C72

P2860

Q24240962-14580850-B23D-4ED7-B08C-2D77941CF3FD

Q24240962-19106D17-FCD2-47FB-95B6-CE0D9ED92C53

Q24240962-2197A52E-49F1-48DB-B17E-B54CD873DBBB

Q24240962-2244604F-4508-4C7E-9A9D-ABD57F5D655A

Q24240962-24FEE626-9440-45CE-B2E2-7ACC600B9D35

Q24240962-3112131A-9427-4B45-9DCB-DF660D83E5FD

Q24240962-35495B6F-76C1-45D9-B62E-7C08A57B8708

Q24240962-376A9EC7-86B4-452C-87E3-ED0E36914848

Q24240962-440F5355-6A6A-4749-BFD6-754ED31E5941

Q24240962-49D1F672-FB4D-4425-92A4-E70D30BB83A5

P31

Q24240962-AC6CCD52-70E2-40ED-956A-78B12D63C609

P356

Q24240962-CAB01FB0-DF52-4B84-98B8-C00DB0AFFF55

P50

Q24240962-100F7CF0-0560-46BC-8935-DBE7EC1F57DF

P577

Q24240962-BC592E4C-BB6A-4C23-A652-048E10159E7E

P698

Q24240962-51AE276B-9601-4441-A895-60C901CE89D0

P921

Q24240962-643EA407-82BF-47CD-B55A-8B2B1871A46F

Q24240962-8779E292-15A4-423F-B4F2-1A3826ADE31D

P356

14651858.CD007287.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Antigen-specific active immunotherapy for ovarian cancer

@en

P2093

Ben J Cohlen

http://www.w3.org/2001/XMLSchema#string

H Marike Boezen

http://www.w3.org/2001/XMLSchema#string

Hans W Nijman

http://www.w3.org/2001/XMLSchema#string

Kees Melief

http://www.w3.org/2001/XMLSchema#string

Ninke Leffers

http://www.w3.org/2001/XMLSchema#string

Wijnand Helfrich

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Evaluating non-randomised intervention studies

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.

P31

scholarly article

P356

10.1002/14651858.CD007287.PUB2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20091627

http://www.w3.org/2001/XMLSchema#string

P921